Novo Nordisk A/S (NYSE:NVO) Receives $133.60 Consensus Target Price from Analysts

Shares of Novo Nordisk A/S (NYSE:NVO) have received an average rating of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $133.60.

A number of research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. UBS Group assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective for the company. Finally, BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target for the company.

Institutional Trading of Novo Nordisk A/S

Several institutional investors have recently modified their holdings of the stock. Cravens & Co Advisors LLC lifted its position in shares of Novo Nordisk A/S by 1.0% during the 1st quarter. Cravens & Co Advisors LLC now owns 8,250 shares of the company’s stock worth $1,059,000 after buying an additional 85 shares during the last quarter. Sage Rhino Capital LLC lifted its position in shares of Novo Nordisk A/S by 0.7% during the 1st quarter. Sage Rhino Capital LLC now owns 12,320 shares of the company’s stock worth $1,582,000 after buying an additional 89 shares during the last quarter. U.S. Capital Wealth Advisors LLC lifted its position in shares of Novo Nordisk A/S by 0.6% during the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock worth $1,595,000 after buying an additional 90 shares during the last quarter. Essex LLC lifted its position in shares of Novo Nordisk A/S by 2.0% during the 1st quarter. Essex LLC now owns 4,684 shares of the company’s stock worth $601,000 after buying an additional 90 shares during the last quarter. Finally, Clarius Group LLC lifted its position in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock worth $1,914,000 after buying an additional 93 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.8 %

Shares of NVO stock opened at $123.05 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The stock has a market capitalization of $552.19 billion, a P/E ratio of 42.43, a price-to-earnings-growth ratio of 2.06 and a beta of 0.43. The company has a 50 day moving average price of $127.20 and a 200 day moving average price of $113.10. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.